The class III effect of azimilide is not associated with reverse use- dependence in open-chest dogs

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 898-903

  Qi, Xiang Qian ^a   Newman, David ^a   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Azimilide; Refractoriness; Repolarization; Reverse use dependence

Indexed keywords

AZIMILIDE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTERIAL PRESSURE; ARTICLE; DOG; ELECTROGRAPHY; FEMALE; HEART RATE; HEART REPOLARIZATION; HEART RIGHT VENTRICLE; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; PRIORITY JOURNAL; SINUS RHYTHM;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BLOOD PRESSURE; CARDIAC PACING, ARTIFICIAL; DELAYED RECTIFIER POTASSIUM CHANNELS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; IMIDAZOLES; IMIDAZOLIDINES; MALE; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; VENTRICULAR FIBRILLATION;

EID: 0032748427     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00019     Document Type: Article

References (27)

1. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachycardias. N Engl J Med 1993;329: 452-8.
2. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:685-90.
3. Strauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 1970;26:661-78.
4. Dangman KH, Miura DS. Effects of therapeutic concentrations of procainamide on transmembrane action potentials of normal and infarct zone Purkinje fibers and ventricular muscle cells. J Cardiovasc Pharmacol 1989;13:846-52.
5. Refsum H, Amlie JP, Platou ES, Owren T, Landmark K. Electrophysiological effects of melperone in the dog heart in situ: a new antiarrhythmic drug. Cardiovasc Res 1981;15:131-6.
6. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiologic effects of the class III antiarrhythmic agents sematilide and clofilium. J Cardiovasc Pharmacol 1991;18:167-74.
7. K blocking drug, UK-68,789: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-10.
8. Ks play a role in the reverse rate dependence of class III agents? Circ Res 1996;78:26-37.
9. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998;37:627-35.
10. Busch AE, Herzer T, Takumi T, Krippeit-Drews P, Waldegger S, Lang F. Blockade of human Isk channels expressed in Xenopus oocytes by the novel class III antiarrhythmic NE-10064. Eur J Pharmacol 1994;264:33-7.
11. Busch AE, Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J. The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit Isk channels expressed in Xenopus oocytes and Iks in guinea pig cardiac myocytes. Biochem Biophys Res Commun 1994; 202:265-70.
12. McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 1994;23:653-7.
13. Drexler AP, Micklas JM, Brooks RR. Effects of intravenously administered NE-10064 on programmed electrical stimulation (PES)-induced ventricular arrhythmias in anesthetized infarcted dogs [Abstract]. FASEB J 1993;7:558.
14. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-8.
15. Misier AR, Opthof T, van Hemel NM, Vermeulen JT, de Bakker JM, Defauw JJ, van Capelle FJ, Janse MJ. Dispersion of refractoriness in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation 1995;91:2566-72.
16. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
17. Katritsis D, Camm AJ. New class III antiarrhythmic drugs. Eur Heart J 1993;14(suppl H):93-9.
18. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-71.
19. K block and lack of reverse use dependence in cat ventricular myocytes. Cardiovasc Res 1993;27:1580-91.
20. Schmitt C, Brachmann J, Karch M, et al. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potential of the right ventricle. Am J Cardiol 1991;68:1183-7.
21. Sager PT, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness: electrophysiologic action of sematilide HCL in humans. Circulation 1993;88: 1072-82.
22. Groh WJ, Gibson KJ, Maylie JG. Azimilide (NE-10064) prolongs action potential duration in a reverse rate-dependent manner in guinea pig ventricular muscle [Abstract]. PACE 1995;18:853.
23. Vinet A, Cardinal R, LeFrance P, Hélie F, Rocque P, Kus T, Pagé P. Cycle length dynamics and spatial stability at the onset of post-infarction monomorphic ventricular tachycardias induced in patients and canine preparations. Circulation 1996;93:1845-59.
24. c interval with minor hemodynamic effects in anesthetized dogs [Abstract]. Can J Physiol Pharmacol 1994;72:79.
25. Brandt MA, Maynard AE. NE-10064 exhibits class III antiarrhythmic effect after intravenous or oral administration in conscious dogs [Abstract]. FASEB J 1994;8:A7.
26. Schreieck J, Wang Y, Gjini V, Korth M, Zrenner B, Schomig A, Schmitt C. Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol 1997;8:1420-30.
27. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 1998;38:441-50.